Complete Mobile Drug Testing

Every employer in America faces the same uncomfortable reality: a drug-free workplace is not a preference — it is a federal mandate in regulated industries, a liability shield in litigation, and increasingly a baseline expectation from insurance carriers and enterprise clients. The question is not whether workplace drug testing is necessary; it is who executes it with speed, documentation integrity, and regulatory compliance. Complete Mobile Drug Testing was founded in 2011 in Greenfield, Wisconsin, to solve exactly that problem for employers who cannot afford to send workers off-site or wait days for results. Headquartered in the Milwaukee metropolitan area, the company was built by a certified woman-owned business (CWOB) leadership team that identified a structural gap between what traditional testing labs offer and what modern employers — especially those operating under Department of Transportation mandates — actually need: on-site, 24/7, mobile-first compliance testing that eliminates downtime and maintains unimpeachable chain of custody. Complete Mobile Drug Testing began franchising in 2010, expanding the model nationally and growing to 34 units across the United States, with services trusted by Fortune 500 companies. The franchise is positioned within the B2B compliance services sector, a category defined by recurring demand, long-term employer contracts, and near-zero consumer discretionary risk. The total addressable market for drug testing globally is estimated at USD 15.07 billion in 2025, with projections reaching USD 21.50 billion by 2032 — a compound annual growth rate of 5.2%. Complete Mobile Drug Testing's franchise opportunity sits at the intersection of regulatory necessity and operational convenience, making it a brand that independent analysts at PeerSense track as a functionally differentiated entry in the compliance services franchise space.

The drug testing and screening industry is one of the most structurally resilient segments in the entire franchise marketplace, and the macroeconomic forces driving its growth are neither cyclical nor discretionary. The global drug testing market was valued at USD 13.91 billion in 2024 and is projected to reach USD 18.62 billion by 2030 at a CAGR of 5.1%, while a separate segment analysis of the drug screening market places its 2025 value at USD 8.49 billion and forecasts growth from USD 9.86 billion in 2026 to USD 20.86 billion by 2031, representing a dramatically higher CAGR of 16.16% during that forecast window. Even the most conservative projections — estimating the global drug screening market at USD 7.09 billion in 2026 growing to USD 10.85 billion by 2035 at a CAGR of 4.84% — confirm a consistent, multi-decade growth story that franchise investors in other categories rarely encounter. North America leads the global market, commanding a 39.7% share in 2025, which means the U.S. domestic opportunity represents the single largest pool of addressable employer demand anywhere in the world. Complete Mobile Drug Testing describes the industry itself as a "$5 billion-plus industry with consistent growth" and specifically characterizes it as recession-resistant — a designation that carries real weight given that DOT-regulated employers are legally required to conduct drug testing regardless of macroeconomic conditions. The competitive landscape remains relatively fragmented at the local and regional service-delivery level, despite the presence of large national lab networks, because the mobile on-site model requires local operator relationships, regulatory fluency, and rapid deployment capability that centralized labs structurally cannot provide. Key demand drivers include expanding DOT compliance requirements across trucking, aviation, and rail sectors, growing employer adoption of pre-employment and random testing protocols, rising insurance carrier mandates, and heightened post-pandemic awareness of workplace safety liability — all of which create durable, contract-based revenue streams for franchisees operating under the Complete Mobile Drug Testing system.

The Complete Mobile Drug Testing franchise cost structure reflects a capital-efficient, mobile-first business model that deliberately eliminates the overhead burden of brick-and-mortar retail lab operations. The franchise fee is $50,000, and the total investment range spans from $72,350 to $123,150 — a notably compressed range compared to many service franchise categories, driven by the absence of physical build-out requirements, leasehold improvements, and retail inventory. For context, comparable mobile drug testing franchise models in the market carry franchise fees ranging from $34,900 to $99,900 and total investment ranges from $62,000 to $167,249, which positions the Complete Mobile Drug Testing franchise investment in the mid-tier of its direct category while remaining dramatically more accessible than most brick-and-mortar franchise formats. The minimum liquid capital required to qualify is $100,000, and the minimum net worth requirement is $150,000 — thresholds that reflect the relatively lean operational footprint of the model while ensuring franchisees have sufficient financial cushion to sustain operations through the client acquisition ramp-up period. Third-party financing is available through the Complete Mobile Drug Testing system, which broadens accessibility for qualified candidates who may not have the full investment range in liquid assets. The capital-efficiency ratio of this model is a meaningful differentiator: with a total investment ceiling of $123,150 and no traditional storefront overhead, franchisees are deploying capital almost entirely into operational capability, territory rights, training, and working capital rather than into real estate and construction. When evaluated against service-sector franchise benchmarks, this investment profile places Complete Mobile Drug Testing in the accessible-to-mid-tier range — well below the $200,000-plus thresholds common in food service franchises and competitive with high-performing B2B service franchise categories. Prospective investors should conduct thorough review of the Franchise Disclosure Document to identify all ongoing fee obligations including royalty structure, technology platform fees, and any required marketing contributions before finalizing investment decisions.

The operating model of a Complete Mobile Drug Testing franchise is built around B2B service delivery to employers, job sites, regulated industries, offices, and facilities that require on-site drug and compliance testing without the logistical disruption of sending employees off-site. The company's approximately 6-person corporate team supports franchisees through what CMDT describes as full training and comprehensive ongoing support, including continuous training, marketing assistance, and operational guidance. The service portfolio that franchisees deliver is deliberately comprehensive: DOT collections, non-DOT collections, background screening, fingerprinting, DNA testing, paperless chain of custody management, web-based ordering and result tracking, rapid turnaround times, and consortium management for DOT compliance — a bundled offering that creates natural cross-sell and upsell opportunities within each employer client relationship. The mobile-first format means franchisees operate without the fixed overhead of a lab facility, deploying to client locations 24 hours a day, 7 days a week, which is a structural service advantage over traditional testing facilities with limited operating hours. CMDT's technology stack — which includes MySQL database infrastructure, PHP programming, jQuery Validation, and web-based client access tools — underpins a paperless, digitally documented chain of custody process that meets federal regulatory standards and provides clients with real-time result tracking. The territory model grants franchisees a protected geographic area, with the ownership structure described as territory-based and designed explicitly for expansion and long-term value creation, suggesting a pathway for multi-territory growth as franchisees build their employer client base. Training is described as full and comprehensive, with ongoing operational assistance continuously available — a support model designed to enable franchisees without prior drug testing industry experience to become competent compliance service providers, a claim reinforced by the company's DATIA (Drug and Alcohol Testing Industry Association) membership, which signals adherence to recognized industry professional standards.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Complete Mobile Drug Testing, which means prospective franchisees will not find average revenue per unit, median revenue figures, or profit margin data within the FDD itself. This is a meaningful due diligence consideration: the Federal Trade Commission does not require franchisors to disclose financial performance representations in Item 19, but when franchisors choose not to disclose, investors must build their financial models from external data sources, industry benchmarks, and franchisee validation interviews. What is publicly available provides useful directional context: Complete Mobile Drug Testing reports estimated annual company revenue of approximately $878,000 at the corporate operating level, which provides a reference data point for what a mature operator in this service category can generate. For comparison, mobile drug testing franchise operators in the broader market have cited net annual earnings figures in the range of $145,745, though such figures require careful scrutiny since they represent earnings after costs rather than top-line revenue and may reflect varying territory sizes and client base maturity levels. The B2B compliance services model has a structural advantage over consumer-facing franchises in that revenue is largely driven by recurring employer contracts — pre-employment screening programs, random testing pools, DOT compliance programs, and annual background screening agreements — which creates more predictable revenue cadence than transaction-based retail formats. The mobile service model's low fixed overhead means that contribution margins on each service call are structurally higher than in facility-based models, where lease costs, utilities, and buildout depreciation create a heavier fixed cost burden. Investors conducting due diligence on the Complete Mobile Drug Testing franchise revenue potential should request franchisee contact information from Item 20 of the FDD, speak directly with existing franchisees about gross revenue ranges and ramp timelines, and model conservative, base case, and optimistic scenarios using industry CAGR data and local employer market sizing as inputs.

Complete Mobile Drug Testing has grown to 34 franchise units since beginning franchising in 2010, establishing a network footprint that spans the United States with services confirmed to be in use by Fortune 500 companies — a client validation signal that carries meaningful weight for prospective franchisees evaluating brand credibility with large employer accounts. The 15-year franchising track record, from 2010 through the present, represents a brand that has survived economic cycles including the 2008-2009 recession's tail effects, the post-2012 regulatory expansion of DOT random testing requirements, and the COVID-19 pandemic period — all of which either maintained or increased employer demand for compliant drug testing services. CMDT's DATIA membership and CWOB (Certified Woman-Owned Business) certification provide differentiated positioning in enterprise procurement environments where supplier diversity certifications and industry association credentials influence vendor selection decisions, particularly in government contracting and large-employer RFP processes. The company's technology infrastructure investments — including web-based ordering and tracking, paperless chain of custody, and a modern development stack — represent ongoing operational modernization that keeps franchisees competitive against both legacy lab-based providers and newer point-of-care testing alternatives. The recession-resistant designation the company applies to its industry category is supported by the structural fact that DOT-regulated employers — including motor carriers, aviation operators, pipeline operators, and transit agencies — face federal penalties for non-compliance with drug testing mandates, making their testing expenditure essentially non-discretionary. The global drug testing market's projected growth from USD 15.07 billion in 2025 to USD 21.50 billion by 2032 at a 5.2% CAGR means franchisees entering the Complete Mobile Drug Testing system today are positioning themselves ahead of approximately seven years of documented market expansion, with North America's 39.7% global market share ensuring that domestic franchisees are operating in the world's single largest and most compliance-regulated employer testing market.

The ideal Complete Mobile Drug Testing franchise candidate is a B2B relationship builder — someone with background in sales, account management, human resources, occupational health, compliance, transportation, or business development who understands how to earn and maintain trust with employer decision-makers including HR directors, safety managers, fleet managers, and operations executives. The franchise model does not require prior drug testing or laboratory experience, as the training and support infrastructure is designed to bring operators up to professional competency; however, candidates with existing professional networks in DOT-regulated industries, staffing, or occupational health services will have a measurable advantage in accelerating their client acquisition timeline. The territory-based ownership structure is designed explicitly for expansion, which means single-territory operators who demonstrate strong performance have a natural pathway to acquiring additional protected territories and building a multi-territory portfolio — a growth model that is common among the highest-earning franchisees in B2B service franchise categories. Available territories are currently advertised by Complete Mobile Drug Testing, and prospective franchisees should request a current territory availability map early in the discovery process since protected territory rights are typically granted on a first-qualified-buyer basis. The mobile service format requires minimal lead time from signing to operational launch compared to build-out-dependent franchises, as there is no construction timeline or lease negotiation process for a physical facility — a meaningful advantage for investors who want to begin generating revenue quickly. Third-party financing availability reduces the barrier for otherwise qualified candidates who need to preserve liquid capital above the $100,000 minimum requirement, and the total investment ceiling of $123,150 makes SBA microloan and SBA 7(a) program conversations worth exploring with qualified lenders during the due diligence process.

The investment thesis for the Complete Mobile Drug Testing franchise opportunity is grounded in four compounding advantages that are difficult to find simultaneously in a single franchise concept: a structurally non-discretionary B2B demand base driven by federal regulatory mandates, a capital-efficient mobile operating model with a total investment ceiling of $123,150, a confirmed 34-unit national network with Fortune 500 client validation, and a global industry projected to grow from USD 15.07 billion in 2025 to USD 21.50 billion by 2032. These structural factors do not guarantee individual franchisee success — territory quality, sales execution, client retention, and operational consistency all remain decisive variables — but they establish a market and business model context that warrants serious due diligence from investors evaluating B2B service franchise categories. The recession-resistant designation is not marketing language; it is a function of the federal compliance architecture that makes drug testing mandatory for regulated employers regardless of economic conditions, a durability characteristic that most consumer-facing franchise categories cannot credibly claim. For investors evaluating this opportunity with rigor, PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark Complete Mobile Drug Testing against comparable B2B service franchise concepts across investment cost, unit count growth, territory availability, and franchisee satisfaction indicators. Explore the complete Complete Mobile Drug Testing franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make your investment evaluation with the most comprehensive, unbiased data available anywhere on the internet.